By Mimi Nguyen Ly
Group to meet with other regulators to discuss potentially updating current vaccines
The European Union’s drug regulator expressed doubts about whether a second booster dose of the currently available COVID-19 vaccines would be a sustainable long-term approach.
Marco Cavaleri, the European Medicines Agency’s (EMA) head of vaccines strategy, told a media briefing, “There is an emergency discussion around the possibility of giving a second booster dose with the same vaccine currently in use. Data has not yet been generated to support this approach.”
“We have not yet seen data with respect to a fourth dose,” he also said later. “We would like to see this data before we can make any recommendation, but at the same time we are rather concerned about a strategy that [involves] repeated vaccinations within a short term.”
Cavaleri said an additional booster shot “could be considered as part of a contingency plan,” but “repeated vaccinations within short intervals will not represent a sustainable long term strategy.”
Concerns Over Immune Response
When asked to expand on his statements, Cavaleri said that for a hypothetical approach of giving boosters frequently, such as every four months, “we will end up potentially having problems with immune response and immune response may end up not being as good as we would like it to be, so we should be careful in not overloading the immune system with repeated immunization.”
He added that continuous administration of boosters can also lead to fatigue in the population.
“It will be much better to start thinking about an administration of boosters that is more spaced in time,” Cavaleri said.
The EMA is in conversation with vaccine developers in case there is a need to update the current vaccines, he said, but noted that any change “would have to be coordinated globally.”
Meanwhile, more data on the impact of the new variant—in this case, Omicron—on vaccines and a better understanding of the evolution of the current wave were needed to decide whether an Omicron-specific vaccine was needed.
“While a monovalent Omicron vaccine would represent an obvious candidate to be investigated, other options such as a multivalent vaccine cannot be ruled out as potential alternatives,” Cavaleri said.
A Strategy to ‘Anticipate the Next Move’
He added, “It is important that there is a good discussion around the choice of the composition of the vaccine to make sure that we have a strategy that is not just reactive after the virus changes, but try to anticipate what could be the next move, and try to come up with an approach that will be suitable in order to prevent a future variant that, in any case, will emerge.”
The EMA has called for a meeting with global regulators on Wednesday, which will include officials from the U.S. Food and Drug Administration.
“Tomorrow we will be looking at all the evidence that we have so far with the current vaccine, so the extent by which they are still providing vaccine effectiveness and whether indeed we should still think that giving a booster shot at this point in time is the best strategy,” Cavaleri said.
He added that the World Health Organization (WHO) “will play a critical role” in decision-making.
Cavaleri noted that the CCP (Chinese Communist Party) virus, which causes COVID-19, “is still behaving as a pandemic virus, and the Omicron emergency is currently showing that.”
“So we should not forget we are still in a pandemic. Nevertheless, with increase of immunity in the population and with Omicron there will be a lot of natural immunity taking place on top of vaccination, we will be vastly moving toward a scenario that will be closer to endemicity,” he said.
Separately, he noted, “Ideally, if you want to move toward a scenario of endemicity, then such boosters should be synchronized with the arrival of the cold seasons in each of the hemispheres, similarly to what we’re doing with influenza vaccines.”
Pfizer Looking at Omicron-Targeted Vaccine
On Monday, Pfizer CEO Albert Bourla said a COVID-19 vaccine that specifically targets the Omicron variant of the virus as well as already circulating variants “will be ready in March,” adding that the company is “already starting manufacturing some of these quantities at risk.”
Bourla said Pfizer is ready to file for U.S. regulatory approval for the redesigned COVID-19 vaccine, and that the company has built up ample manufacturing capacity, such that it will not be a problem to switch immediately. He also noted on Monday that COVID-19 vaccines eventually could be an annual shot for most people, and some high-risk groups might be eligible to receive the shots more often than that.
On Tuesday, Cavaleri said that April or May would be the soonest the EMA could approve any variant-targeted vaccine.
“In terms of the switch of the manufacturing, this is a decision that is beyond EMA and it will be very important there is a global discussion around the best option here in the interest of public health,” he commented.
Reuters contributed to this report.
Affiliate News Feeds
- Washington Examiner
- The Federalist
- The Epoch Times
- The Guardian
- The Gateway Pundit
- Judicial Watch
By Patricia Tolson A new survey reveals that the majority of Americans do not trust the integrity of America’s elections. According to a poll conducted among likely General Election voters between Nov. 16–20… [...]
By Louise Chambers When her neighbor, a farmer, fell ill suddenly, a Minnesota teen volunteered to help him tend the land. The farmer was beyond grateful for the support, and the teen… [...]
Sen. Marco Rubio (R-FL) announced on Tuesday that he won’t support legislation to prevent an economically calamitous rail strike if it isn’t supported by the union workers. [...]
The Pentagon believes the Chinese military’s nuclear arsenal can more than triple by 2035. [...]
Abusers in homes across the nation and worldwide have utilized chemical abortion pills in the same way that Herring allegedly did. [...]
Even amid the hedonistic holiday mania, people are still eager to have a fulfilling and joyful Christmas. Christians can help. [...]
Philadelphia District Attorney Larry Krasner “Ignores reality and claims Philadelphia does not have a crisis of crime,” according to the third and final report of the Pennsylvania House Select Committee… [...]
U.S. Rep. Matt Cartwright (D-Pa.) on Tuesday sued the board of elections of a Pennsylvania county that didn’t have enough paper ballots on Election Day for failing to certify his victory by… [...]
Antibody therapy lecanemab removes clumps of protein called beta amyloid that builds up in brainResearchers have hailed the dawn of a new era of Alzheimer’s therapies after a clinical trial… [...]
Groups C and D conclude: check the latest permutationsDaily briefing: the joy of Mbappé, Argentina’s escape planGet in touch: email Martin with your thoughtsThe TV numbers are in. 16.59 million… [...]
As the war against censorship seeps into nearly every facet of our lives, best selling rapper Bryson Gray will soon find out if his stand for free speech and artistic… [...]
While the corporate media such as the New York Times and Wall Street Journal have been writing puff pieces about mega democrat donor Sam Bankman-Fried, independent journalist Ben Armstrong better… [...]
Though years ago India passed a sweeping law giving transgender people rights—and prohibiting discrimination in education, employment, and healthcare—the Biden administration is spending American taxpayer dollars to counter stigma and… [...]
(Washington, DC) – Judicial Watch announced today that it filed a Freedom of Information Act (FOIA) lawsuit against the Department of Homeland Security (DHS) for all communications between the Secret… [...]